YOLFTbeta
Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

SNDX · NASDAQ · Healthcare / Biotechnology

9.45USD-0.09 (-0.94%)

Price History

Full chart

Market Stats

Previous Close9.54
Open9.73
Day Range9.11 – 9.85
52-Week Range12.99 – 25.59
Volume3.18M
Market Cap1.63B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.51
Dividend Yield0.00%
Beta0.37
50-Day Avg19.68
200-Day Avg20.93

About

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Michael A. Metzger M.B.A.
  • Employees298
  • Headquarters730 Third Avenue, New York, NY, United States, 10017, USA
  • Websitehttps://syndax.com

Leadership

  • Mr. Michael A. Metzger M.B.A.CEO & Director · b. 1971
  • Mr. Keith Alan Goldan CPACFO, Treasurer & Principal Accounting Officer · b. 1971
  • Mr. Luke J. Albrecht J.D.Senior VP, General Counsel & Secretary · b. 1979
  • Dr. Nicholas A.J. Botwood B.Sc., MBBSHead of Research & Development and Chief Medical Officer · b. 1968
  • Dr. Peter Ordentlich B.Sc., Ph.D.Co-Founder & Chief Scientific Officer · b. 1969
  • Dr. Richard A. Heyman Ph.D.Co-Founder · b. 1957
  • Dr. Ronald M. Evans Ph.D.Co-Founder, Advisor and Chair of Scientific Advisory Board · b. 1950
  • Dr. Michael Downes Ph.D.Co-Founder
  • Sharon KlahreVice President of Investor Relations & Communications

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---0627.00K1.22M2.11M1.52M1.52M1.52M139.71M126.58M023.68M172.35M
Growth (%)-----+94.58%+72.79%-28.04%0.00%0.00%+9109.56%-9.40%-100.00%-+627.84%
Cost of Revenue51.00K--021.12M41.70M63.99M0--456.00K454.00K12.00K826.00K6.97M
Gross Profit-51.00K--0627.00K1.22M2.11M1.52M1.52M1.52M139.71M-454.00K-12.00K22.85M165.38M
Gross Margin----100.00%100.00%100.00%100.00%100.00%100.00%100.00%-0.36%-96.51%95.96%
Operating Expense9.57M--21.33M21.14M44.99M64.06M77.39M59.06M72.94M113.49M151.30M229.94M362.53M438.47M
Operating Income-9.62M-8.73M-8.57M-21.33M-20.51M-43.77M-61.95M-75.88M-57.54M-71.42M26.22M-151.76M-229.95M-339.67M-273.08M
Operating Margin-----3271.61%-3587.38%-2938.99%-5001.71%-3792.95%-4708.17%18.77%-119.89%--1434.43%-158.45%
EBITDA-11.05M-5.26M-8.56M-21.32M-20.49M-43.68M-61.88M-75.80M-57.45M-71.33M26.26M-151.72M-209.14M-313.82M-251.63M
EBITDA Margin-----3268.26%-3580.08%-2935.39%-4996.57%-3786.88%-4702.31%18.80%-119.87%--1325.26%-146.00%
Net Income-13.09M-9.96M-14.17M-19.83M-24.12M-44.47M-60.80M-73.96M-55.95M-73.07M24.93M-143.75M-209.36M-318.76M-285.42M
Net Income Margin-----3846.73%-3645.25%-2884.35%-4875.48%-3688.53%-4816.68%17.84%-113.57%--1346.11%-165.60%
R&D6.09M5.24M3.21M10.18M9.55M31.66M48.20M60.11M42.99M50.44M88.25M118.50M163.03M241.65M258.78M
R&D as % of Total Revenue----1522.97%2595.49%2286.57%3962.16%2834.15%3324.65%63.17%93.62%-1020.47%150.15%
Interest Expense1.99M0001.57M956.00K1.42M1.94M1.57M2.36M1.90M3.14M208.00K4.93M33.78M
Interest Expense % of Total Revenue----251.20%78.36%67.41%128.02%103.56%155.37%1.36%2.48%-20.82%19.60%

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.79M1.51M17.06M12.82M89.90M109.01M137.19M83.94M63.52M300.61M449.66M497.24M612.88M724.82M529.71M
Total Liabilities23.84M30.80M5.21M18.53M23.20M24.87M32.87M30.89M31.93M48.42M41.29M29.79M58.68M436.69M465.08M
Total Equity-19.05M-29.29M11.85M-5.72M66.70M84.14M104.32M53.05M31.60M252.19M408.37M467.45M554.20M288.12M64.63M
Cash3.70M537.00K10.10M10.01M23.18M23.84M35.17M33.77M24.61M115.24M221.97M74.36M295.39M154.08M134.93M
Total Debt19.34M21.34M-13.88M----897.00K20.54M20.97M1.16M1.64M345.74M346.48M
Net Debt15.64M20.81M-10.10M3.88M-23.18M-23.84M-35.17M-33.77M-23.71M-94.71M-201.00M-73.19M-293.76M191.66M211.55M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-10.02M-9.28M-7.29M-14.39M-2.43M-35.16M-47.37M-68.53M-50.61M-71.26M29.13M-133.68M-160.60M-274.90M-322.98M
Investing Cash Flow2.19M494.00K-4.03M1.89M-61.67M-18.38M-17.03M51.40M12.78M-142.53M-40.87M-186.19M117.61M-219.78M290.04M
Financing Cash Flow8.63M5.71M20.89M12.41M77.27M54.20M75.72M15.73M28.57M304.42M118.46M172.25M264.13M353.37M13.68M
Capital Expenditure8.00K11.00K38.00K4.00K49.00K261.00K84.00K187.00K129.00K129.00K129.00K225.00K00187.00K
Free Cash Flow-10.03M-9.29M-7.33M-14.40M-2.48M-35.42M-47.45M-68.72M-50.61M-71.26M29.00M-133.90M-160.60M-274.90M-323.17M
Dividends Paid-----2.60M---------
FCF to OCF100.08%100.12%100.52%100.03%102.02%100.74%100.18%100.27%100.00%100.00%99.56%100.17%100.00%100.00%100.06%
Dividend Paid to FCF------7.34%---------

Earnings

Report DateMay 16, 2016Aug 9, 2016Nov 10, 2016Mar 2, 2017May 8, 2017Aug 10, 2017Nov 7, 2017Mar 5, 2018May 8, 2018Aug 7, 2018Nov 5, 2018Mar 7, 2019May 6, 2019Aug 7, 2019Nov 7, 2019Mar 3, 2020May 7, 2020Aug 6, 2020Nov 2, 2020Mar 8, 2021May 11, 2021Aug 9, 2021Nov 15, 2021Mar 1, 2022May 9, 2022Aug 8, 2022Nov 3, 2022Feb 28, 2023May 8, 2023Aug 3, 2023Nov 2, 2023Feb 27, 2024May 8, 2024Aug 1, 2024Nov 5, 2024Feb 25, 2025May 5, 2025Aug 4, 2025Nov 3, 2025Feb 26, 2026Apr 30, 2026Aug 4, 2026Nov 2, 2026
EPS Estimate-0.48-0.54-0.82-0.73-0.71-0.82-0.82-0.78-0.95-0.89-0.76-0.67-0.55-0.47-0.48-0.43-0.51-0.44-0.43-0.49-0.64-0.73-0.570.28-0.68-0.62-0.63-0.65-0.61-0.75-0.80-0.97-0.98-0.91-1.06-0.23-1.27-1.01-0.71-0.64-0.59-0.45-0.51
EPS Actual-0.73-0.47-0.84-0.59-0.71-0.70-0.68-0.80-0.79-0.74-0.68-0.70-0.53-0.47-0.41-0.44-0.56-0.42-0.46-0.44-0.54-0.44-0.401.81-0.63-0.62-0.58-0.62-0.59-0.64-0.73-1.00-0.85-0.80-0.98-1.10-0.98-0.83-0.70-0.78-0.48-0.55-
Surprise-52.08%12.96%-2.44%19.18%0.00%14.63%17.07%-2.56%16.84%16.85%10.53%-4.48%3.64%0.00%14.58%-2.33%-9.80%4.55%-6.98%10.20%15.63%39.73%29.82%546.43%7.35%0.00%7.94%4.62%3.28%14.67%8.75%-3.09%13.27%12.09%7.55%-380.56%22.83%17.82%1.41%-21.88%18.64%-22.22%-
TimingAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap1.63B
Enterprise Value1.61B
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales6.39
Price / Book104.32
EPS-2.51
Book Value0.169
Revenue (TTM)252.25M
Gross Profit (TTM)-20.20M
EBITDA-194.16M
Profit Margin-87.52%
Operating Margin-54.95%
Return on Equity-255.93%
Return on Assets-18.67%
Shares Outstanding89.30M
Shares Float80.30M
Beta0.37
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 12 analystsTarget 37.55
  • Strong Buy
    9
  • Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
126.12%
Insiders
1.69%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    8.25M9.24%
  • Kynam Capital Management, LP
    8.05M9.02%
  • The Goldman Sachs Group Inc
    5.00M5.60%
  • State Street Corp
    4.43M4.96%
  • Bank of America Corp
    4.25M4.76%
  • Vanguard Capital Management, LLC
    3.82M4.28%
  • Deerfield Management Co
    3.78M4.23%
  • Eversept Partners, LP
    2.80M3.13%
  • Kingdon Capital Management LLC
    2.50M2.80%
  • StemPoint Capital LP
    2.43M2.72%
  • Hood River Capital Management LLC
    2.35M2.64%
  • Geode Capital Management, LLC
    2.16M2.42%
  • Franklin Templeton Inc
    2.15M2.41%
  • Millennium Management LLC
    2.05M2.30%
  • Point72 Asset Management, L.P.
    1.99M2.22%
  • Elmind Capital LP
    1.85M2.08%
  • Vanguard Portfolio Management, LLC
    1.74M1.95%

Top Fund Holders

  • State Street® SPDR® S&P® Biotech ETF
    3.71M4.16%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.83M3.17%
  • iShares Russell 2000 ETF
    2.28M2.55%